Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel.

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons.

The aim of this randomized, multicenter study was to evaluate the safety and effectiveness of the biolimus-coated balloon (BCB) in patients with small-vessel coronary artery disease (reference vessel diameter 2.0 to 2.75 mm and length ≤25 mm) undergoing coronary angioplasty.

The primary endpoint (PEP) was vessel lumen narrowing at 9 months as measured by angiography. The secondary endpoint (SEP) included restenosis, and procedural, lesion, and device success.

Clinical outcomes were evaluated up to a 1-year follow-up and included cardiovascular death, treated-vessel-related acute myocardial infarction, clinically guided revascularization, and treated-vessel failure, among others.

A total of 212 patients were included and randomized as follows: 106 to the BCB group and 103 to the balloon angioplasty group; the remaining 3 were excluded because they did not receive the device.

Read also: Should We Start Thinking Again About Bioresorbable Stents?

Mean patient age was 61 years old, and 30% of subjects were female. The most frequent clinical presentation was unstable angina. The number of lesions treated in >95% of patients was 1. Pre-dilation was achieved in all cases and the number of pre-dilations in most patients was 1.

For the PEP, BCB was superior to balloon angioplasty (p = 0.001). The restenosis rate was lower in the BCB group, with 9.9% vs. 28% in the balloon group (p = 0.001). There were no differences in the SEP nor in clinical events at 1 year.

Conclusion

This randomized study has demonstrated the safety and efficacy of the new biolimus-coated balloon in patients with small-vessel coronary artery disease. Positive vascular remodeling was 3 times more frequent when using these devices, and there was a non-significant trend in clinical improvement at 1 year.

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org.

Original Title: Biolimus-Coated Balloon in Small-Vessel Coronary Artery Disease The BIO-RISE CHINA Study.

Reference: Kai Xu, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Hyper-Adducted Right Radial Access vs. Left Radial Access: Aiming for Lower Daily Radiation Exposure

Interventional cardiologists face one of the most extreme occupational hazards: ionizing radiation. The right radial access (RRA) has been established as the preferred alternative...

Fasting versus No Fasting Before Percutaneous Cardiovascular Procedures

While the American Society of Anesthesiologists guidelines were updated in 2017 to allow for the intake of clear liquids up to two hours and...

Smoking and Its Impact on Cardiovascular Disease 10 Years After Coronary Angioplasty

Smoking is a well-established risk factor for atherosclerotic cardiovascular diseases. However, some historical reports have suggested a lower risk of adverse cardiovascular events in...

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

One-Year Mortality Trends Following TAVR: STS/ACC TVT Registry Outcomes

Transcatheter aortic valve replacement (TAVR) has quickly consolidated as a safe and effective treatment option for patients with severe symptomatic aortic stenosis. At present,...

Hyper-Adducted Right Radial Access vs. Left Radial Access: Aiming for Lower Daily Radiation Exposure

Interventional cardiologists face one of the most extreme occupational hazards: ionizing radiation. The right radial access (RRA) has been established as the preferred alternative...

Is Transcarotid Access a Safe Option in TAVI?

Transcatheter aortic valve implantation (TAVI) should preferably be conducted via transfemoral access, according to European guideline (in patients ≥75 years) and American guideline (in patients...